Saturday 17 October 2026
Export CYTK’s income statement to Excel — free account
Cytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024. In the quarter to June 2026, revenue fell 57.1%, EPS fell 33.9%, free cash flow fell 24.0% and total debt rose 57.7%, each against the same quarter a year earlier.
61.95
1.97
−3.08%
Follow CYTK
Cytokinetics, Incorporated (CYTK) P/E ratio
Cytokinetics, Incorporated has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 243× (April 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 32.6× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 243×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CYTK Cytokinetics, Incorporated | n/m |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | n/m |
| AXSM Axsome Therapeutics, Inc. compare | n/m |
| TGTX TG Therapeutics, Inc. compare | 17.8× |
| KRYS Krystal Biotech, Inc. compare | 38.3× |
| CAI Caris Life Sciences,�Inc. compare | 81.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 106× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)